DC_AC50
DC_AC50 性质
| 沸点 | 485.1±45.0 °C(Predicted) |
|---|---|
| 密度 | 1.759±0.06 g/cm3(Predicted) |
| 储存条件 | 2-8°C |
| 溶解度 | 溶于二甲基亚砜 |
| 酸度系数(pKa) | 8.80±0.70(Predicted) |
| 形态 | 粉末 |
| 颜色 | 白色至浅棕色 |
DC_AC50 用途与合成方法
DC_AC50 exhibits IC
50
values of 9.88 μM, 12.57 μM, 5.96 μM and 6.68 μM in Canine Abrams, Canine D1, human HOS and human MG63) cells, respectively.
DC_AC50 (0-10 μM)-treated cells are significantly less mitotically active, as demonstrated by decreased expression of phospho-histone H3 and cell cycle analysis.
DC_AC50 (10 μM) potentiates carboplatin-induced apoptosis in OSA cells and decreasesclonogenic survival.
DC_AC50 induces cell cycle arrest at both the 3 and 10 μM doses and DC_AC50 induces increase S phase cells dose-independently.
DC_AC50 (3 μM) inhibits the migration and of canine and human OSA cells.
DC_AC50 (2.5-10 μM) is highly efficient at inhibiting cancer cell proliferation (human lung cancer H1299 cells, leukaemia cancer K562 cells, breast cancer MDA-MB-231 cells and head and neck cancer 212LN cells) in a dose-dependent manner. DC_AC50 fails to exhibit any notable inhibition of the cell proliferation of human normal epithelial lung BEAS-2B cells or breast MCF-10A cells as control cells.
Cell Viability Assay
| Cell Line: | Canine OSA (Abrams, D1 and human OSA (HOS, MG63) cells. |
| Concentration: | 0-10 μM. |
| Incubation Time: | 72 h. |
| Result: | Dose-dependently decreased viability of OSA cells. |
Apoptosis Analysis
| Cell Line: | Abrams and HOS cells. |
| Concentration: | 1, 3 and 10 μM (10 μM Carboplatin). |
| Incubation Time: | 24 h. |
| Result: | Potentiated carboplatin-induced apoptosis. |
DC_AC50 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-04-30 | HY-107636 | 1 mg | 386 | ||
| 2024-04-30 | HY-107636 | DC_AC50 | 497061-48-0 | 5mg | 850 |
